Overview

A Multicentre Investigation of 2 Cycles Rituximab Compared With Standard Regimen in Management of Steroid-Resistant/Relapsed Immune Thrombocytopenia （ITP）

Status:
Withdrawn

Trial end date:
2016-01-01

Target enrollment:

Participant gender:

Summary

The project was undertaking by Qilu Hospital, Shandong University and other several well-known hospitals in China. In order to report the efficacy and safety of Rituximab in different frequencies for the treatment of adults with steroid-resistant/relapsed immune thrombocytopenia (ITP).

Phase:

Phase 3

Details

Lead Sponsor:

Shandong University

Treatments:

Rituximab